Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

NCT03211247 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

414

Enrollment

INDUSTRY

Sponsor class

Conditions

Peanut Allergy

Interventions

BIOLOGICAL: Part A Viaskin Peanut 250 mcg
BIOLOGICAL: Part A Viaskin Peanut 100 mcg
BIOLOGICAL: Part A Placebo
BIOLOGICAL: Part B Viaskin Peanut 250 mcg
BIOLOGICAL: Part B Placebo

Sponsor

DBV Technologies